Related Experiment Video
Updated: May 1, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Posterior reversible encephalopathy syndrome with PLEDs-plus due to mesalamine
Ajith Cherian1, C V Soumya1, Thomas Iype1
1Department of Neurology, Government Medical College, Trivandrum, Kerala, India.
Abstract:
A 32-year-old lady developed status epilepticus and acute visual loss while on mesalamine for Crohn's disease. Her clinical course and magnetic resonance imaging (MRI) were suggestive of posterior reversible encephalopathy syndrome (PRES). She had periodic lateralized epileptiform discharges plus (PLEDs-plus) on electroencephalogram (EEG), which responded to sodium valproate. Her vision improved from counting fingers at one-meter distance to 6/12. Though different cytotoxic drugs have been implicated as causative agents, this is the first case report of mesalamine-induced PRES. This case highlights the need for aggressive treatment of PLEDs-plus with EEG monitoring using a broad-spectrum antiepileptic drug like valproate, which has contributed to the rapid reversibility of vision in PRES subjects, and the need for a thorough drug history for etiological clues.
More Related Videos
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
04:55A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Hepatic Encephalopathy
Encephalitis l: Introduction
Inflammatory Bowel Disease II: Ulcerative Colitis
Encephalitis ll: Pathophysiology
Multiple Sclerosis l: Introduction